The true costs of Eczema in Europe

Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe

The European Atopic Dermatitis (EAD) Working Group, a multidisciplinary panel comprised of international dermatology clinicians, a health economist, and a patient advocacy group representative of the UK Eczema Outreach Support was created to raise awareness of the difficulty and challenges in the treatment of Atopic Dermatitis and unveil the cost of Eczema in Europe.

Patients with Atopic Dermatitis experience a reduction in daily activities, sleep deprivation, increased hospital visits, complications in interpersonal relationships, burdensome personal costs, mental health challenges, and an increased absence from work and school, with an average of 5.5 – 11.3 days for adults, in children resulting at 2.5 days of school resulting in 2.5 days for a parent caring for the child.

The annual economic burden is 30 billion euros

For adults living with moderate to severe AD, the annual economic burden is 30 billion euros, comprised of direct costs, personal costs, and indirect costs. Between the quality of life and financial burden, care that includes educational and family support and multidisciplinary and individualized care are essential factors in managing AD.

Whitepaper and patient-friendly infographics

A full white paper, supported by Sanofi Genzyme, was written and published in the Journal of the European Academy of Dermatology and Venerology (JEADV). Please take a moment to review the accompanying infographic for a patient-friendly summary.

Learn more about Atopic Dermatitis (Eczema) on GAAPP´s website

Infographics